NO20015149D0 - Nytt farmasöytisk preparat - Google Patents

Nytt farmasöytisk preparat

Info

Publication number: NO20015149D0
Authority: NO; Norway
Prior art keywords: pharmaceutical preparation; new pharmaceutical; new; preparation; pharmaceutical
Prior art date: 1999-04-23

Application number

NO20015149A

Other languages

English (en)

Other versions

NO20015149L (no

NO320589B1 (no

Inventor

Paul David James Blackler

Robert Gordon Giles

Michael John Sasse

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-23

Filing date

2001-10-22

Publication date

2001-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015149(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-23 Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en

1999-05-25 Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en

2001-10-22 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-10-22 Publication of NO20015149D0 publication Critical patent/NO20015149D0/no

2001-12-17 Publication of NO20015149L publication Critical patent/NO20015149L/no

2005-12-27 Publication of NO320589B1 publication Critical patent/NO320589B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Steroid Compounds (AREA)

NO20015149A 1999-04-23 2001-10-22 Polymorf, anvendelse og fremstilling derav, samt farmasoytisk preparat. NO320589B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9909472.4A GB9909472D0 (en)	1999-04-23	1999-04-23	Novel compounds
GBGB9912197.2A GB9912197D0 (en)	1999-05-25	1999-05-25	Novel pharmaceutical
PCT/GB2000/001514 WO2000064892A2 (en)	1999-04-23	2000-04-19	Thiazolidinedione derivative and its use as antidiabetic

Publications (3)

Publication Number	Publication Date
NO20015149D0 true NO20015149D0 (no)	2001-10-22
NO20015149L NO20015149L (no)	2001-12-17
NO320589B1 NO320589B1 (no)	2005-12-27

Family

ID=26315460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015149A NO320589B1 (no)	1999-04-23	2001-10-22	Polymorf, anvendelse og fremstilling derav, samt farmasoytisk preparat.

Country Status (40)

Country	Link
US (2)	US6815457B1 (no)
EP (3)	EP1284268B1 (no)
JP (1)	JP2002543075A (no)
KR (1)	KR100744359B1 (no)
CN (1)	CN1208335C (no)
AP (1)	AP1495A (no)
AR (2)	AR023568A1 (no)
AT (2)	ATE247653T1 (no)
AU (1)	AU765498B2 (no)
BG (1)	BG65427B1 (no)
BR (1)	BR0009934A (no)
CA (1)	CA2370258A1 (no)
CO (1)	CO5170424A1 (no)
CY (1)	CY1107238T1 (no)
CZ (1)	CZ20013799A3 (no)
DE (2)	DE60004658T2 (no)
DK (2)	DK1284268T3 (no)
DZ (1)	DZ3155A1 (no)
EA (1)	EA004534B1 (no)
ES (2)	ES2204557T3 (no)
HK (1)	HK1045154B (no)
HR (1)	HRP20010773B1 (no)
HU (1)	HUP0200929A3 (no)
IL (1)	IL146110A0 (no)
MA (1)	MA26785A1 (no)
MX (1)	MXPA01010820A (no)
MY (1)	MY128007A (no)
NO (1)	NO320589B1 (no)
NZ (1)	NZ515163A (no)
OA (1)	OA11871A (no)
PE (1)	PE20010040A1 (no)
PL (1)	PL351686A1 (no)
PT (2)	PT1284268E (no)
RS (1)	RS50114B (no)
SK (1)	SK286423B6 (no)
TR (1)	TR200103061T2 (no)
TW (1)	TW591027B (no)
UA (1)	UA67843C2 (no)
UY (1)	UY26120A1 (no)
WO (1)	WO2000064892A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020137940A1 (en)	1997-12-16	2002-09-26	Smithkline Beecham P.L.C.	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
US6664278B2 (en)	1997-12-16	2003-12-16	Smithkline Beecham P.L.C.	Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20040248945A1 (en)	1999-04-23	2004-12-09	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
ATE246191T1 (de) *	1999-04-23	2003-08-15	Smithkline Beecham Plc	Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
BR0009934A (pt)	1999-04-23	2002-06-04	Smithkline Beecham Plc	Produto farmacêutico
GB0006133D0 (en)	2000-03-14	2000-05-03	Smithkline Beecham Plc	Novel pharmaceutical
US7241895B2 (en) *	2000-09-26	2007-07-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
PL360661A1 (en) *	2000-09-26	2004-09-20	Dr.Reddy's Research Foundation	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2003050116A1 (en) *	2001-12-13	2003-06-19	Smithkline Beecham Plc	A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
AU2002352479A1 (en) *	2001-12-20	2003-07-09	Smithkline Beecham Plc	5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) *	2001-12-20	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0307259D0 (en) *	2003-03-28	2003-05-07	Glaxo Group Ltd	Process
EP1468997A3 (en) *	2003-04-18	2004-11-03	CHEMI S.p.A.	Polymorphous forms of rosiglitazone maleate
GB2405403A (en) *	2003-08-29	2005-03-02	Cipla Ltd	Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005073227A2 (en) *	2004-01-28	2005-08-11	Usv Limited	A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
ITMI20041537A1 (it) *	2004-07-28	2004-10-28	Chemi Spa	Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) *	2005-05-24	2007-09-26	Zentiva, A. S.	Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) *	2006-05-09	2008-10-14	Teva Pharmaceutical Industries, Ltd.	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched rosiglitazone
EP2184055A1 (en)	2008-11-07	2010-05-12	LEK Pharmaceuticals d.d.	Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0306228B1 (en)	1987-09-04	1999-11-17	Beecham Group Plc	Substituted thiazolidinedione derivatives
US6288095B1 (en)	1987-09-04	2001-09-11	Beecham Group P.L.C.	Compounds
GB9124513D0 (en)	1991-11-19	1992-01-08	Smithkline Beecham Plc	Novel process
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5741803A (en)	1992-09-05	1998-04-21	Smithkline Beecham Plc	Substituted thiazolidinedionle derivatives
US5457109A (en) *	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4404198A1 (de)	1994-02-10	1995-08-17	Henkel Kgaa	2-Fluor-6-nitroaniline
WO1995021608A1 (en)	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases
US20010044458A1 (en) *	1994-02-10	2001-11-22	Smithkline Beechamp P.L.C.	Use of insulin sensitisers for treating renal diseases
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) *	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
GB9711683D0 (en)	1997-06-05	1997-08-06	Smithkline Beecham Plc	Composition
CZ298469B6 (cs)	1997-06-18	2007-10-10	Smithkline Beecham Plc	Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
GB9712866D0 (en)	1997-06-18	1997-08-20	Smithkline Beecham Plc	Novel method of treatment
US20020028768A1 (en) *	1997-06-18	2002-03-07	Smithkline Beecham P.L.C.	Treatment of diabetes with rosiglitazone and insulin
US20010049380A1 (en) *	1997-06-18	2001-12-06	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and sulphonylurea
ATE353654T1 (de)	1997-06-18	2007-03-15	Smithkline Beecham Plc	Behandlung der diabetes mit thiazolidindione und sulphonylurea
WO1998057635A1 (en)	1997-06-18	1998-12-23	Smithkline Beecham Plc	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
US20020045649A1 (en) *	1997-07-18	2002-04-18	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) *	1997-07-18	2002-02-07	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9726563D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
US20020137940A1 (en)	1997-12-16	2002-09-26	Smithkline Beecham P.L.C.	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
GB9726566D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
JP2002543076A (ja)	1999-04-23	2002-12-17	スミスクラインビーチャムパブリックリミテッドカンパニー	チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
BR0009934A (pt)	1999-04-23	2002-06-04	Smithkline Beecham Plc	Produto farmacêutico
ATE246191T1 (de)	1999-04-23	2003-08-15	Smithkline Beecham Plc	Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
PL360661A1 (en)	2000-09-26	2004-09-20	Dr.Reddy's Research Foundation	Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

2000
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 EP EP02080320A patent/EP1284268B1/en not_active Expired - Lifetime
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active Expired - Fee Related
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 EP EP00920889A patent/EP1173434B1/en not_active Expired - Lifetime
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 EP EP07150378A patent/EP1903043A1/en not_active Withdrawn
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/xx active
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-19 HK HK02104882.1A patent/HK1045154B/en not_active IP Right Cessation
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/en not_active Ceased
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 CA CA002370258A patent/CA2370258A1/en not_active Abandoned
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
2001
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown

Also Published As

Publication number	Publication date
CA2370258A1 (en)	2000-11-02
MA26785A1 (fr)	2004-12-20
EP1173434A2 (en)	2002-01-23
PT1284268E (pt)	2008-03-10
AU4130600A (en)	2000-11-10
HUP0200929A3 (en)	2004-03-29
AR023564A1 (es)	2002-09-04
ATE247653T1 (de)	2003-09-15
EA004534B1 (ru)	2004-06-24
AU765498B2 (en)	2003-09-18
UA67843C2 (uk)	2004-07-15
TW591027B (en)	2004-06-11
DE60004658T2 (de)	2004-06-24
WO2000064892A3 (en)	2001-01-25
PT1173434E (pt)	2003-12-31
DE60004658D1 (de)	2003-09-25
PL351686A1 (en)	2003-06-02
HK1045154B (en)	2004-06-25
CO5170424A1 (es)	2002-06-27
RS50114B (sr)	2009-03-25
WO2000064892A2 (en)	2000-11-02
YU75201A (sh)	2004-09-03
ES2298327T3 (es)	2008-05-16
TR200103061T2 (tr)	2002-05-21
MXPA01010820A (es)	2002-06-04
DE60037602T2 (de)	2009-01-08
EP1284268B1 (en)	2007-12-26
SK286423B6 (sk)	2008-09-05
NO20015149L (no)	2001-12-17
DK1173434T3 (da)	2003-12-08
EP1284268A1 (en)	2003-02-19
US20040092555A1 (en)	2004-05-13
KR100744359B1 (ko)	2007-07-30
HRP20010773B1 (en)	2005-06-30
JP2002543075A (ja)	2002-12-17
US6815457B1 (en)	2004-11-09
UY26120A1 (es)	2000-12-29
ES2204557T3 (es)	2004-05-01
NZ515163A (en)	2004-02-27
HK1045154A1 (en)	2002-11-15
CN1355801A (zh)	2002-06-26
IL146110A0 (en)	2002-07-25
BG106119A (en)	2002-05-31
CY1107238T1 (el)	2012-11-21
MY128007A (en)	2007-01-31
OA11871A (en)	2006-03-27
DZ3155A1 (fr)	2000-11-02
DE60037602D1 (de)	2008-02-07
NO320589B1 (no)	2005-12-27
EP1903043A1 (en)	2008-03-26
BR0009934A (pt)	2002-06-04
EA200101119A1 (ru)	2002-04-25
AP1495A (en)	2005-11-30
CZ20013799A3 (cs)	2002-04-17
HK1055293A1 (en)	2004-01-02
AR023568A1 (es)	2002-09-04
PE20010040A1 (es)	2001-03-10
BG65427B1 (bg)	2008-07-31
DK1284268T3 (da)	2008-04-28
ATE382046T1 (de)	2008-01-15
KR20020028873A (ko)	2002-04-17
SK14912001A3 (sk)	2002-02-05
CN1208335C (zh)	2005-06-29
EP1173434B1 (en)	2003-08-20
HRP20010773A2 (en)	2002-10-31
HUP0200929A2 (en)	2002-08-28

Publication	Publication Date	Title
NO20030418L (no)	2003-01-27	Nytt farmasöytisk preparat
NO20033143L (no)	2003-09-19	Farmasoytisk preparat
FI991485L (fi)	2000-12-31	Uusi farmaseuttinen koostumus
NO20005399L (no)	2000-10-26	Farmasöytisk preparat
NO20015175L (no)	2001-10-23	Farmasöytisk sammensetning
DE60038698D1 (de)	2008-06-05	Hydrogel-gesteuerte dosierungsform
FIU20000164U0 (fi)	2000-04-11	Uusi farmaseuttinen formulaatio
PT1242087E (pt)	2004-06-30	Composicoes farmaceuticas
NO20015149D0 (no)	2001-10-22	Nytt farmasöytisk preparat
EE200200150A (et)	2003-04-15	Preparaat
DK1466615T3 (da)	2009-08-31	Farmaceutisk præparat
NO20015670L (no)	2001-11-20	Forbedrede farmasöytiske formuleringer
NO20022606D0 (no)	2002-05-31	Farmasöytiske kombinasjoner
NO20025805L (no)	2003-06-06	Farmasöytisk preparat
NO20015148L (no)	2001-12-17	Nytt farmasöytisk preparat
NO20014926D0 (no)	2001-10-10	Farmasöytiske forbindelser
NO20015104L (no)	2001-12-19	Nytt farmasöytisk preparat
FI4488U1 (fi)	2000-07-20	Farmaseuttinen koostumus
NO20015105D0 (no)	2001-10-19	Nytt farmasöytisk preparat
AR025867A1 (es)	2002-12-18	Formulacion portasdora farmaceutica
EE200100697A (et)	2003-02-17	Farmatseutiline kompleks
NO20021036L (no)	2002-04-26	Farmasöytisk preparat
NO20004816D0 (no)	2000-09-26	Ny farmasøytisk formulering
NO20022541D0 (no)	2002-05-29	Fast preparat
NO20014450D0 (no)	2001-09-13	Farmasöytisk preparat basert på polyaromatiske forbindelser